IDEAYA Biosciences (IDYA) Competitors $26.79 +0.19 (+0.71%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IDYA vs. CPRX, XENE, OSMT, CUE, TXMD, ITCI, ROIV, ASND, LEGN, and ELANShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Catalyst Pharmaceuticals (CPRX), Xenon Pharmaceuticals (XENE), Osmotica Pharmaceuticals (OSMT), Cue Biopharma (CUE), TherapeuticsMD (TXMD), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector. IDEAYA Biosciences vs. Catalyst Pharmaceuticals Xenon Pharmaceuticals Osmotica Pharmaceuticals Cue Biopharma TherapeuticsMD Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Catalyst Pharmaceuticals (NASDAQ:CPRX) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has better earnings and valuation, CPRX or IDYA? Catalyst Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$460.48M5.56$71.41M$1.1818.20IDEAYA Biosciences$3.92M590.39-$112.96M-$2.33-11.50 Which has more volatility & risk, CPRX or IDYA? Catalyst Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Is CPRX or IDYA more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to IDEAYA Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals31.01% 40.79% 34.87% IDEAYA Biosciences N/A -19.42%-18.63% Do analysts recommend CPRX or IDYA? Catalyst Pharmaceuticals currently has a consensus target price of $31.14, indicating a potential upside of 44.99%. IDEAYA Biosciences has a consensus target price of $53.67, indicating a potential upside of 100.32%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94 Does the MarketBeat Community believe in CPRX or IDYA? Catalyst Pharmaceuticals received 356 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 74.70% of users gave Catalyst Pharmaceuticals an outperform vote while only 70.98% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformCatalyst PharmaceuticalsOutperform Votes49374.70% Underperform Votes16725.30% IDEAYA BiosciencesOutperform Votes13770.98% Underperform Votes5629.02% Does the media refer more to CPRX or IDYA? In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 9 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.78 beat IDEAYA Biosciences' score of 0.24 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in CPRX or IDYA? 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryCatalyst Pharmaceuticals beats IDEAYA Biosciences on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.32B$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-11.5011.05105.0417.81Price / Sales590.39361.961,233.12158.46Price / CashN/A52.5940.4136.29Price / Book1.9610.377.096.50Net Income-$112.96M$153.60M$119.65M$226.22M7 Day Performance0.56%4.60%2.25%4.03%1 Month Performance-9.19%-6.29%-2.34%4.92%1 Year Performance-15.22%33.41%33.97%29.30% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.179 of 5 stars$26.79+0.7%$53.67+100.3%-15.2%$2.32B$3.92M-11.5080High Trading VolumeCPRXCatalyst Pharmaceuticals4.7017 of 5 stars$21.33+1.0%$31.14+46.0%+55.0%$2.54B$460.48M17.90167XENEXenon Pharmaceuticals3.5584 of 5 stars$40.54+1.9%$57.45+41.7%+43.2%$3.09B$9.43M-14.17251Insider TradeOSMTOsmotica PharmaceuticalsN/AN/AN/AN/A$69.47M$177.88M-0.70302CUECue Biopharma4.4711 of 5 stars$1.08+4.9%$5.00+363.0%-57.3%$52.53M$5.49M-1.1460TXMDTherapeuticsMD0.1828 of 5 stars$1.35+1.5%N/A-50.7%$15.57M$1.60M0.00420Analyst ForecastITCIIntra-Cellular Therapies4.4537 of 5 stars$85.18-0.3%$97.23+14.1%+44.6%$9.03B$612.78M-98.22560Positive NewsROIVRoivant Sciences3.337 of 5 stars$12.02+1.7%$17.93+49.2%+39.2%$8.89B$124.79M2.10860Insider TradeASNDAscendis Pharma A/S2.9978 of 5 stars$123.96+1.1%$191.77+54.7%+39.6%$7.52B$327.43M-15.22640Analyst UpgradeLEGNLegend Biotech1.4505 of 5 stars$39.67-0.2%$81.46+105.3%-31.9%$7.23B$285.14M-41.841,800ELANElanco Animal Health3.8657 of 5 stars$13.36-0.3%$17.14+28.3%+11.9%$6.60B$4.42B33.519,300 Related Companies and Tools Related Companies Catalyst Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Osmotica Pharmaceuticals Alternatives Cue Biopharma Alternatives TherapeuticsMD Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDYA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
